Emerging Technologies and Partnerships in Drug Delivery - April 27-28, 2005 - Philadelphia, PA

Emerging Technologies and Partnerships in Drug Delivery
April 27-28, 2005 - Philadelphia, PA
Emerging Technologies and Partnerships in Drug Delivery
This annual event provides the industry with a best practices forum for identifying collaborations, strategies and technologies for product commercialization. This industry standard event is the optimal place to hear from over 20 elite faculty members on key topics including:
Nanotechnology
Regulations
IP
Competitive Intelligence
Investment Trends
Protein and Peptide Drug Delivery
Assessing Technologies
Specialty Pharmaceuticals
Life Cycle Management
In addition to providing critical business strategies, the program features sessions and a technology showcase highlighting the hottest technologies available today:
Implants
Injectables
Nasal
Needle-free
Oral
Pulmonary
Transdermal
Don?t miss this unique opportunity to learn from the industry?s top performers, network with the market?s top players and hear in-depth information about cutting-edge technology.
Who Should Attend
You will benefit from attending this event if you are an executive or senior level director from the pharmaceutical or biotech industries with responsibilities or involvement in the following areas:
R&D
Analytical R&D
Business Development
Commercial Development
Licensing and Patent Development
Formulation Development
Life Cycle Management
New Product Development
Technology Assessment
This conference will also be of interest to drug delivery companies, investment bankers, venture capital companies and business development consultants.
Distinguished Speakers
Sue Masters, Lead Business Analyst Drug Delivery Engineering, Amgen
Jonas Pedersen, Director, Competitive Intelligence, Amgen
Peter Noymer, Ph.D., Director of systems Engineering, Aradigm
Jonathan Rigby, Senior Director of Business Development, Aradigm
Jean Surian, Ph.D., Associate Principal Scientist, Drug Delivery Manager, AstraZeneca
John Fraher, President of North American Sales, Eurand
Peter Larsen, Vice President, Global Business Development, BioValve Technologies
Ronald L. Smith, Ph.D., Executive Director Exploratory Biopharmaceutics & Stability, Bristol-Myers Squibb Company
Michael J. Valazza, R.Ph., Vice President, Business Development, Cardinal Health
Amin Khan, Ph.D., Distinguished Research Fellow, Eli Lilly
Vik Seoni, Senior Director, Business Development, Endo Pharmaceuticals
Larry Brown, Sc.D., Chief Technology Officer, Epic Therapeutics Inc.
John Fraher, President of North America Sales, Eurand
Natasha Leskovsek, Attorney, Heller Ehrman White and MCAuliffe
Rajeeve Gokhale, Senior Research Fellow, Merck & Co., Inc.
Vijay Tammara, Ph.D., Director, Regulatory Affairs, Merck & Co., Inc.
Elaine Liversidge, Director, NanoSystems/Elan Drug Delivery Inc.
Stefanie Hansen, Associate Director, Strategic Alliances, Pfizer Global Research and Development
Jerry S. Dahl, PE, Principle Scientist Engineer, Pfizer Inc
Makarand Jawadekar, Assistant Director, Pharmaceutical Sciences, Pfizer Inc
Amir Nashat, Principal, Polaris Ventures
Ian Sanderson, Managing Director, SG Cowen
Robert Hazlett, Senior Research Analyst; Managing Director, Suntrust Robinson Humphrey
James R. Baker, Jr., M.D., Director, Center for Biologic Nanotechnology, University of Michigan